MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MAIA Biotechnology (MAIA) reported updated interim efficacy data for ateganosine in its Phase 2 THIO-101 expansion trial in advanced non-small cell lung cancer.
Across Parts A, B and C, disease control was 88% (38 of 43 patients) as of October 01, 2026, among third-line patients evaluable for efficacy who had at least one tumor scan after starting treatment. Disease control means stable disease or better. Patients had progressed after prior immunotherapy and chemotherapy. Reported disease control for standard third-line chemotherapy regimens was 25%–35%; this is a historical comparison.
Part C enrollment is complete. Ateganosine has FDA Fast Track designation, and MAIA said further Part C data may support an accelerated approval filing. The ongoing pivotal Phase 3 THIO-104 trial targets the same population, with an interim survival analysis planned for 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointDisease control reached 88% (38 of 43 patients) across THIO-101 Parts A–C, versus historical chemotherapy reports of 25%–35%.
- Minor pointPart C enrollment is complete in the Phase 2 THIO-101 expansion trial.
- Minor pointFDA Fast Track designation applies to ateganosine’s development.
- Minor point. Forward-looking: it has not happened yet and may not happen.Further Part C data may support an accelerated approval filing, MAIA said.
- Minor point. Forward-looking: it has not happened yet and may not happen.Pivotal Phase 3 THIO-104 is ongoing, with an interim survival analysis planned for 2027.
Negative
- Minor pointInterim efficacy results cover only 43 evaluable patients with at least one post-treatment tumor scan.
Key Figures
- Disease control rate
- 88% (38 of 43 patients)
- Parts A, B and C; as of October 1, 2026; efficacy-evaluable patients with at least one post-treatment tumor scan
- Standard chemotherapy disease control
- 25%–35%
- Reported range for standard third-line chemotherapy regimens
- Interim survival analysis
- 2027
- THIO-104 Phase 3 trial milestone
- Ateganosine dose
- 180 mg
- Followed by cemiplimab in 21-day cycles
Previous Clinical trial Reports
-
THIO-101 enrollment was complete and the company reported interim disease control data.
-
Initial Part C results reported disease control with ateganosine followed by cemiplimab.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
disease control rate medical
overall survival medical
pd-(l)1 inhibition medical
fast track designation regulatory
accelerated approval regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MAIA advances novel telomere-targeting agent under FDA’s Fast Track designation
Further data from THIO-101 Part C may support accelerated approval filing with FDA
CHICAGO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). THIO-101 Part C is evaluating additional patients to confirm the strong efficacy data observed in Parts A and B of the study.
The Phase 2 trial assesses advanced NSCLC patients who were nonresponsive or developed resistance and progressed after prior immune checkpoint inhibitor therapy and chemotherapy. Patients are treated with ateganosine 180mg followed by cemiplimab (Libtayo®) in cycles of 21 days. The sequential administration of ateganosine followed by PD-(L)1 inhibition is intended to enhance and prolong the antitumor immune response.
“It is encouraging to see an
For Parts A, B, and C of THIO-101 as of October 01, 2026, the observed disease control rate (DCR) for third-line NSCLC patients resistant to chemo and immunotherapy is
MAIA has completed enrollment in Part C of its Phase 2 THIO-101 expansion, which enrolled patients in Hungary, Poland, Turkey, Georgia, Romania, Taiwan, and in the United States. Concurrently, an ongoing pivotal Phase 3 clinical trial of third line ateganosine treatment, THIO-104, with the same target population as THIO-101 Part C, is advancing toward regulatory milestones including 2027 interim survival analysis.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About THIO-101 Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
1 Matsumoto H, et al. Transl Lung Cancer Res 2021;10:2278–89
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.